10-K · March 2, 2026
Geron Corporation's 10-K filing for the year ending December 31, 2025, highlights a robust year marked by a significant increase in revenue from its FDA-approved therapy, RYTELO®, resulting in a total annual revenue of…
Earnings analysis · 10-Q
GERN earnings analysis
Filed May 6, 2026 · Our reading of the company's report
The latest report
Geron Corporation reported Q1 2026 results with revenue of $51.8 million, exceeding estimates and the previous year by 31%. Gross margin improved slightly, while EPS of -$0.01 reflected a notable decrease in losses…
Read full summary
Geron Corporation reported Q1 2026 results with revenue of $51.8 million, exceeding estimates and the previous year by 31%. Gross margin improved slightly, while EPS of -$0.01 reflected a notable decrease in losses compared to the same quarter last year. Management's commentary indicated ongoing challenges with commercialization despite positive revenue trends from their only product, RYTELO, for treating lower-risk MDS. They reiterated potential risks relating to regulatory scrutiny and competition.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.01
- Segment
- RYTELO Sales
What stood out
-
Q1 Revenue Growth of 31%
Revenue reached $51.8 million, up from $39.6 million in Q1 2025.
-
EPS Loss Narrowed to -$0.01
EPS improved from -$0.03 in Q1 2025.
-
Positive Revenue Surprise of 2.43%
Actual revenue of $51.8 million beat estimates of $50.5 million.
-
Cost Containment Efforts
Total operating expenses decreased by 8% to $51.7 million from $56.3 million.
-
Cash Position Remains Strong
Cash, cash equivalents, and marketable securities totaled $341 million as of March 31, 2026.
-
Revised Cash Flow Outlook
Despite increasing operational cash used to $62.9 million, improved revenue mitigated some concerns.
What to watch
-
High Dependence on RYTELO Sales
Future profitability remains dependent on RYTELO's commercial success, which is still uncertain.
-
Existing Lawsuits Could Incite Costs
Ongoing legal matters may divert resources and result in financial liabilities.
-
Regulatory Compliance Risks
Potential challenges in maintaining regulatory approval, particularly for product safety and effectiveness.
Management's outlook
Management provided no explicit numeric guidance for future quarters.
Earlier filings 4
10-Q · November 7, 2025
Geron Corporation reported Q3 results with revenue of $47M, falling short of the expected $53M and demonstrating a 67% rise from the prior year. The adjusted EPS loss improved slightly to -$0.03, reflecting operational…
10-Q · August 6, 2025
Geron Corporation reported stronger-than-expected Q2 2025 results, with revenues of $49 million, up from $40 million in Q1 and significantly higher than Q2 2024's $882,000. The company continues to experience…
10-Q · May 7, 2025
Geron Corporation reported Q1 2025 financial results showing revenues of approximately $39.6 million, primarily driven by product sales from its drug RYTELO. Although the gross margin decreased slightly to 97%, the…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.